Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Neoplasms 2Uterine Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoadjuvant Therapy 1Lung Neoplasms 1Kenny-Caffey syndrome, Type 1 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 7Paclitaxel 4Cisplatin 3Carboplatin 3camrelizumab 2Radiotherapy 2Radiosurgery 2Nivolumab 2Immunotherapy 2Immune Checkpoint Inhibitors 2tremelimumab 1toripalimab 1spartalizumab 1sinoporphyrin sodium 1poly ICLC 1penpulimab 1durvalumab 1avelumab 1Tramadol 1Tadalafil 1Surgical Procedures, Operative 1S 1 (combination) 1Radiation 1Poly(ADP-ribose) Polymerase Inhibitors 1Photochemotherapy 1Pemetrexed 1Oxaliplatin 1Morphine 1Leucovorin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Parkinson Disease 4, Autosomal Dominant Lewy Body × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡